jRCT2031210401进行中（未招募）不适用
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 35
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •1.Subject has provided written informed consent.
- •2.Subject is >= 18 years of age at time of Screening.
- •3.Subject has a diagnosis of active PsA for at least 6 months before the first administration of the study agent and has active PsA at Screening or Baseline.
- •4.Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP Ab) negative.
- •5.Subjects must have no prior exposure to anti-tumor necrosis factor (anti-TNF) agent(s) use for the treatment of PsO or PsA.
排除标准
- •1.TheSubject has a planned surgical intervention between Baseline and the Week 52 evaluation for a pretreatment condition.
- •2.Subject has an active infection or history of infections as follows:
- •any active infection for which systemic anti-infectives were used within 28 days prior to first IMP dose, with the last dose having been received within 7 days of Screening,
- •a serious infection, defined as requiring hospitalization or intravenous (IV) anti-infectives within 8 weeks prior to the first IMP dose, with the last dose having been received within 7 days of Screening,
- •recurrent or chronic infections, e.g., chronic pyelonephritis, chronic osteomyelitis, bronchiectasis, or other active infection that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
- •3.Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease (e.g., renal failure, heart failure, hypertension, liver disease, diabetes, or anemia) that, in the opinion of the Investigator, could cause this study to be detrimental to the subject.
- •Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
- •Subject had myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to the first IMP dose.
- •6.Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.
- •7.Subjects with a history of alcohol or drug abuse in the previous 2 years.
- •8.Female subjects of childbearing potential who do not agree to abstain from heterosexual activity or practice a dual method of contraception, for example, a combination of the following: (1) oral contraceptive, depo progesterone, or intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects with female partners of childbearing potential who are not using birth control as described above must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy). Contraceptive methods must be practiced upon signing the Informed Consent and through 24 weeks after the last dose of IMP. If a subject discontinues prematurely, the contraceptive method must be practiced for 17 weeks following final administration of IMP. A follicle-stimulating hormone (FSH) test should be performed to confirm menopause (per reference values of the laboratory) for those women with no menses for less than 1 year.
- •9.Subject currently enrolled in another investigational device/procedure or drug study, or Baseline of this study is less than 30 days or 5 half-lives (whichever is longer) since ending another investigational device/procedure or drug study(s), or receiving other investigational agent(s).
- •10.Subject previously has been enrolled (randomized) in this study.
- •11.Subject has any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.
- •12.Donation or loss of 400 milliliter (mL) or more of blood within 8 weeks before first dose of IMP.
- •13.Subjects who have been placed in an institution on official or judicial orders.
- •14.Subjects who are related to or dependent on the Investigator, Sponsor, or study site such that a conflict of interest could arise.
结局指标
主要结局
-
Primary Endpoint: - The proportion of subjects who achieve ACR20 at Week 24
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Infliximab effectiveness in COVID-19 patientsIRCT20201229049873N1Shahre-kord University of Medical Sciences40
已完成
不适用
The study of the effectiveness of anti-TNF antibody maintenance treatment combined with elemental diet for Crohn's disease patientss diseaseCrohn's diseaseJPRN-UMIN000007343Tohoku University Graduate School of Medicine (Tohoku University Hospital)90
进行中（未招募）
1 期
A study of Tocilizumab in patients with JIA associated Uveitis who have not responded to treatment with an anti-TNF.Juvenile Idiopathic Arthritis with Associated UveitisMedDRA version: 18.0 Level: PT Classification code 10046851 Term: Uveitis System Organ Class: 10015919 - Eye disordersMedDRA version: 18.0 Level: PT Classification code 10059176 Term: Juvenile idiopathic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-001323-23-GBniversity Hospitals Bristol NHS Foundation Trust21
已完成
3 期
Infliximab Plus Methotrexate for the Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00269867Centocor, Inc.428
已完成
不适用
Anti-TNF-Study Utilizing Biomarker Assay to Monitor Early Response to Certolizumab PegolRheumatoid ArthritisJPRN-UMIN000022831niversity of Occupational and Environmental Health, Japan100